Publication

Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib

Abstract
Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.
Author
Rampotas, Alexandros
Carter-Brzezinski, Luke
Somervaille, Tim C
Forryan, James
Panitsas, Fotios P
Harrison, Claire N
Witherall, Ruth
Innes, Andrew J
Wallis, Louise
Butt, Nauman M
Psaila, Bethan
Mead, Adam J
Carter, Matthew
Godfrey, Anna L
Laing, Heather
Garg, Mamta
Francis, Sebastian
Ewing, Joanne
Teh, Chun Huat
Cowan, Hannah B
Dyer, Peter
McConville, Conal
Wadelin, Frances
Ali, Sahra
McGregor, Andrew
Kulakov, Elizabeth
McLornan, Donal P
Lambert, Jonathan
Citations
Altmetric:
Date
2023-11-14
Type
Correspondence
Subject
Dermatology, Oncology. Pathology.
Collections
UHB Dermatology
Show all metadata
Citation
Rampotas A, Carter-Brzezinski L, Somervaille TCP, Forryan J, Panitsas F, Harrison C, Witherall R, Innes AJ, Wallis L, Butt NM, Psaila B, Mead AJ, Carter M, Godfrey AL, Laing H, Garg M, Francis S, Ewing J, Teh CH, Cowen HB, Dyer P, McConville C, Wadelin F, Sahra A, McGregor A, Kulakov E, McLornan DP, Lambert J. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib. Blood. 2024 Jan 11;143(2):178-182. doi: 10.1182/blood.2023022345.
Journal / Source Title
Blood
DOI
10.1182/blood.2023022345
URI
http://hdl.handle.net/20.500.14200/3123
PMID
37963262
Publisher
Elsevier
Publisher’s URL
Publisher’s statement
Note / Copyright